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Abstract
Purpose To evaluate the accuracy of [18F]-choline (FCH)
positron emission tomography/computed tomography (PET/
CT) for staging and restaging of prostate cancer.
Methods FCH PET/CT was performed in 111 patients with
prostate cancer using 200 MBq FCH: 43 patients [mean age
63 years; mean prostrate specific antigen (PSA) 11.58 μg/l]
were examined for initial staging, and 68 patients (mean
age 66.4 years) were examined for restaging (mean PSA
10.81 μg/l). FCH PET/CT results were correlated to
histopathology, bone scan, morphology as revealed by
magnetic resonance imaging (MRI) and CT, PET/CT
follow-up and PSA follow-up after therapy.
Results FCH PET/CT scans at initial staging correctly
showed no metastases in 36/38 patients undergoing radical
surgery, as confirmed by PSA levels <0.1 μg/l 6 months
postoperatively. Lymphadenectomy was performed in 24 of
these patients, revealing four false FCH-negative lymph
nodes (LN). In one patient, only lymphadenectomy was
performed since a FCH-positive LN was confirmed by
histology. Four patients showed FCH-positive bone metas-
tases, as proven by bone scan. FCH PET/CT scans at
restaging correctly revealed local recurrence in 36 patients.
No pathological FCH uptake was observed in 11 patients
with biochemical recurrence. Twenty-three patients showed
FCH-positive LN. Twenty LN were surgically removed in
seven patients. Histopathology verified metastases in all LN,
but revealed two additional metastastic, FCH-negative LN.
Seventeen patients showed FCH-positive bone metastases,
as proven by bone scan or MRI. Sensitivity to detect
recurrent disease was 86%.
Conclusion The results obtained using FCH PET/CT scans
for initial N-staging were discouraging, especially in terms of
its inability to detect small metastases. Recurrent disease can
be localized reliably in patients with PSA levels of >2 μg/l.
Keywords [18F]-Choline . Initial staging . PET-CT.
Prostate cancer . Recurrence
Introduction
In Western Europe and Northern America, Prostate cancer
(PC) is the most common tumour in men and the second
most common cause of death from cancer in North
American men [1]. Prostrate specific antigen (PSA)
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measurement in combination with digital rectal examination
is often used for the early diagnosis of PC, with subsequent
confirmation by transrectal biopsy. Magnetic resonance
imaging (MRI) and transrectal ultrasound are performed to
assess the T stage, while computed tomography (CT) and
bone scan are additionally used for N and M staging.
Depending on the clinical stage, different recommended
treatment options exist, consisting of watchful waiting,
radical prostatectomy, radiotherapy, hormonal therapy or a
combination of these [2]. Following the initial treatment
with curative intent, patients are followed up by serum PSA
measurement supplemented by digital rectal examination
(DRE). Following radical prostatectomy, two consecutive
PSA values of 0.2 μg/l and above are considered to
represent recurrent cancer. After initial radiation therapy,
three consecutive increasing PSA values above the previous
PSA nadir measured at 3-month intervals represent recur-
rent disease [2].
At this level, however, the sensitivity and specificity of
conventional imaging techniques are limited, especially in
terms of localizing the site of recurrence. However, even
more advanced imaging techniques, such as [18F]fluoro-
deoxyglucose (FDG) positron emission tomography (PET),
have been found to be of only limited value for staging and
restaging of PC [3]. Recently, PET using [18F]- or [11C]-
labeled choline analogues as well as [11C]-acetate have
demonstrated promising results in the localization of
recurrent PC [4–10]. The aim of our study was to further
evaluate the accuracy of [18F]choline for the initial staging
and localizing recurrent disease of PC.
Materials and methods
The institutional review board approved the study protocol,
and written informed consent was obtained from all patients
before imaging. The studies were performed between July
2003 and May 2006. The inclusion criteria were: (1) initial
staging: histological proven PC scheduled to undergo surgical
resection; (2) recurrent disease: previously histological proven
PC after treatment with curative intent (surgery, radiation
treatment) and current proven biochemical recurrence.
Patients at initial staging
Forty-three patients (mean age 63 years; range 51–74 years;
SD 6.21 years) with bioptically proven PC eligible for
surgery were examined for initial staging. Biopsy of the
prostate was performed in all of these patients at least
14 days prior to the PET/CT scan (stage information: one,
T1a; two, T1c; 15, T2a; four, T2b; 17, T2c; one, T3; one,
T4). The mean free serum PSA level in these patients was
11.58 μg/l (range 0.6–162 μg/l, SD 24.74), with an average
interval of 56 days (range 0–163 days) between PSA
measurement and PET/CT. The mean Gleason score was
6.79 (range 5–10). Of the 43 patients, 30 were high-risk
patients (high risk defined by PSA >10 μg/l and/or Gleason
≥7). Only one patient was already receiving antihormonal
treatment (PSA 0.6 μg/l at time of PET/CT). The PET/CT
findings were correlated to the histopathological findings of
sampled lymph nodes in 25 patients: 115 lymph nodes;
mean number of removed lymph nodes, 4.6; range, 1–11.
An evaluation of the primary tumour regarding extent was
not performed. PSA follow-up measurements were per-
formed in all 38 patients undergoing radical prostatectomy.
In four of the five patients who did not undergo surgery, a
bone scan (n=4) and MRI (n=1) were performed. In one
nodal positive patient, radical surgery was not performed.
Patients with recurrent disease
Sixty-eight patients (mean age 66.4 years; range 46–81; SD
7.01) were examined due to biochemical recurrence. The
mean free serum PSA level was 10.81 μg/l (range 0.36–
100 μg/l; SD 17.69 μg/l). PSA testing was performed in
different laboratories at various locations prior to referral by
the attending physician. In 53 patients, tumour stage at initial
diagnosis ranged between pT2a and pT4. The initial tumour
stage was not available for 15 patients. The mean Gleason
Score at diagnosis was 7.2 (range 4–10) in 43 patients; for 25
patients the Gleason Score at initial diagnosis was not
available. At the time of the PET/CT scan, 13 patients were
under antihormonal treatment with goserelin (Zoladex) and/
or bicalutamide (Casodex) (n=11) or had undergone
orchiectomy (n=2). Previous therapy is summarized in
Table 1. The interval between the initial treatment and the
PET/CT was 9–115 months. Four patients were scanned
twice after 4, 7, 11 and 18 months, respectively. PET/CT
findings were correlated to PSA follow-up after radiother-
apy, histopathology, MRI, bone scan, clinical follow-up,
follow-up by FCH PET/CT scans (interval 4–18 months) or
apparent changes on the CT part of the PET/CT procedure.
Synthesis of FCH
[18F]-Fluorocholinefluoromethyldimethyl-2-hydroxyethyl-
ammonium (FCH) was produced in-house using the method
as described previously by Schmid et al. [11].
Imaging protocol
The patients were scanned with an integrated PET/CT
scanner (Discovery LS; GE Healthcare) that consists of a
full-ring PET scanner with a 14.6-cm transverse field of
view (FOV) and an in-plane resolution of 4.8 mm full
width at half maximum at the centre of the FOV and a
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multisection CT scanner. A low-dose, unenhanced CT scan
(80 mA, 0.5 s per rotation, 140 kV, 4.25-mm reconstructed
section thickness) was obtained from the head to the pelvic
floor. After the CT scan had been completed, the table
position was moved axially to the initial position for the
PET scanning so that the first FOV started at the ischiadic
tuberosity, covering the pelvic floor and encompassing the
urinary bladder. No indwelling urinary catheter was used
because by scanning the bladder in the first FOV within
5 min of the intravenous injection of FCH, no activity is
found in the bladder, whereas the activity in the prostate
reaches a maximum in this 5-min window immediately
following the injection, as shown by DeGrado et. al. [7].
The PET scan was initiated 120 s after the intravenous
injection of a standard dose of 200 MBq FCH. Six to seven
cradle positions, depending on the size of the patient, with
an acquisition time of 3 min for emission per position were
scanned. CT data were used for attenuation correction of
the PET data and for image fusion. To obtain minimal
attenuation artefacts, a previously described breathing
protocol was used during the CT acquisition [18]. The
PET images were reconstructed with a standard iterative
reconstruction ordered-subset expectation maximization
iterative algorithm (two iterative steps) and were reformat-
ted into transverse, coronal and sagittal views.
Image interpretation
Image analysis was performed in consensus by two nuclear
medicine physicians, one of whom also has a board certificate
in radiology, reading on screen by using PET/CT review
software (XELERIS ver. 1.0728; GE Healthcare), which allows
simultaneous scrolling through the corresponding PET, CT
and fused sections in all three planes. Images were
interpreted as either normal/probably normal if the FCH
uptake was equal to the background or abnormal if the FCH
uptake in a lesion was higher than the background. The
maximum standardized uptake (SUVmax) values were
determined for lesions rated as abnormal. SUVmax values
of the primary tumour in the prostate were not measured at
initial staging as it has been shown that prostate cancer can
not be differentiated from benign prostatic hyperplasia and
prostatitis [11].
Histopathological correlation
In 23 patients who underwent lymphadenectomy, PET/CT
images were compared to histopathological findings. The
surgically resected lymph nodes were fixed in formalin and
embedded in paraffin, and the sections were then stained
with hematoxylin and eosin. A pathologist determined the
exact size of metastases independently.
In patients with a suspicion of recurrent disease, biopsy
of the local recurrence (n=14) or surgical resection of
lymph nodes (n=7) were performed.
Results
Initial staging
Overall results
Pathological FCH uptake in the prostate was observed in 42
of the 43 patients with histological proven PC examined for
initial staging. In only one patient with newly diagnosed PC,
who had already received antihormonal treatment, no
pathological FCH accumulation was delineated in the
prostate. Additional FCH uptake was observed in the lymph
nodes in two patients, in osseous structures in three patients
and in the lymph nodes and osseous structures in one patient.
FCH-positive lymph nodes
In three patients, FCH PET/CT showed FCH-positive
lymph nodes suggestive of lymph node metastases (mean
SUVmax 5.04; range 4.9–5.2; SD 0.21).
In one case with a FCH-positive, pathologically enlarged
obturator lymph node, lymphadenectomy of only this node
was performed, and histopathology revealed a metastasis
greater than 1 cm. The patient did not receive curative therapy
due to concomitant bladder cancer, local progressive prostate
cancer and a history of ear, nose and throat (ENT) cancer.
One patient with a slight FCH accumulation in an iliac
extern lymph node (SUVmax 1.9) underwent radical
Table 1 Initial therapy of patients with recurrent disease
Number of patients Previous therapy
26 RP
4 RP, HT
11 RP, RT
3 RP, RT, HT
8 RT
6 RT, HT
1 Ablatherm
1 HT
1 Hyperthermia
1 RT, HT, Ablatherm
1 RT, HT, RT of a bone metastasis
1 RT, HT, LAD recurrence
1 TURP, HT
1 RP, RT, HT, LAD, Samariumtherapy
2 RP, LAD recurrence
RP, Radical prostatectomy; HT, antihormonal therapy; RT, radiother-
apy external beam or brachytherapy; LAD, lymphadenectomy; TURP,
transurethral resection of the prostate
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prostatectomy and lymphadenectomy in the obturator
region. Histopathology of these lymph nodes did not reveal
metastases. The PSA dropped below 0.04 μg/l within
3 months and remained below 0.04 μg/l for 12 months after
the operation, indicating that the FCH-positive lymph node
did not contain prostate cancer cells and likely represented
instead a reactive lymph node. As such, this lymph node
was defined as a false FCH-positive lymph node in terms of
metastasis.
One patient with bone metastases proven by bone scan
showed FCH accumulation in two pathological enlarged
obturator and iliac extern lymph nodes. Histopathological
correlation was not available. No follow-up FCH PET/CT
was performed in this patient; however, a follow-up bone
scan demonstrated progressive osseous metastases.
Correlation with lymphadenectomy
Histopathological work-up was performed on 115 lymph
nodes sampled from 25 patients. Only one of these lymph
nodes showed pathological FCH accumulation (see above)
and was proven to be a metastasis measuring more than 1 cm.
Four lymph nodes that did not show FCH accumulation
turned out to contain metastatic cells, with an overall tumor
load measuring less than 0.5 cm. All other lymph nodes did
not contain malignant cells. (Tables 2, 3).
Bone metastases
FCH accumulation in osseous lesions was found in four
patients. Bone scan (n=4) and MRI (n=1) verified metastases
in all patients (mean SUVmax 6.3; range 1.8–13.9; SD 4.21).
Correlation with PSA follow-up
Postoperative PSA follow-up was performed in all 38
patients that underwent radical prostatectomy. None of these
patients showed FCH accumulation suggestive of metastatic
disease. Of these 38 patients, 36 showed no measurable PSA
6 months after surgery, demonstrating the absence of
remaining prostatic tissue and thereby verifying the absence
of metastatic disease. The remaining two patients presented
with a detectable PSA 6 months after surgery. One of these
was a patient who had had metastatic disease proven by
histopathology in one of the three lymph nodes that had been
removed; he had a PSA of 0.35 μg/l 6 months after surgery
(pT3a; Gleason 4+5=9). The other patient had a PSA level
of 0.36 μg/l 3 months after R1 resection of the prostatic
tumour (pT2c), explaining the measurable PSA.
Recurrent disease/restaging
Overall results
Pathological FCH accumulation was seen in 57/68 patients
that presented with biochemical recurrence of PC and
examined with FCH PET/CT. The location of pathological
FCH accumulation is summarized in Table 4. FCH PET/CT
was unable to demonstrate the site of recurrent disease in 11
patients, although a biochemical recurrence was present.
Only two of the patients that had a negative PET/CT scan
were under antihormonal therapy. The details of patients
with negative FCH PET/CT scans are summarized in Table 5.
Local recurrence
Local recurrence was FCH positive in a total of 36 patients
(mean SUVmax 2.9; range 1.2–9.7; SD 1.7 ). It was
confirmed by biopsy in 14 patients (Fig. 1) and by a PSA
drop during radiotherapy of the prostatic bed in eight
patients; no antihormonal therapy was given to any patient.
In two patients, the MRI scans were also positive for local
recurrence. Local recurrence was not evaluated in the
remaining 12 patients due to distant metastases and no
clinical significance to the local situation.
Table 2 Histopathology of lymph nodes (initial staging)
Metastasis No metastasis
FCH positive 1 0
FCH negative 4 110
FCH, [18 F]-Fluorocholinefluoromethyldimethyl-2-hydroxyethyl-
ammonium
Table 3 Patients with lymphadenectomy (initial staging)
Metastasis No Metastasis
FCH positive 1 0
FCH negative 2 22
Table 4 FCH accumulation on PET/CT in recurrent disease
FCH accumulation Number of patients
No FCH accumulation 11
Prostatic bed only 19
Prostatic bed and lymph nodes 7
Prostatic bed, lymph nodes and bone 2
Prostatic bed and bone 8
Lymph nodes only 14
Bone only 7
PET/CT, Positron emission tomography/computed tomography
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Lymph node metastases
Pathological FCH accumulation in lymph nodes was found
in 23 patients (mean SUVmax 4.3; range 1–14; SD 2.3).
Lymph node metastases were confirmed by histopathology
in seven patients (total sampled lymph nodes, n=20;
histopathology positive for cancer, n=20). The FCH PET/
CT was positive in 18 of these 20 lymph nodes. In two of
these seven patients, histopathology revealed one addi-
tional lymph node harbouring prostate cancer cells not
seen on FCH PET/CT (2/20 false negative lymph nodes).
In one of the seven, the patient’s PSA remained undetectable
for 16 months after lymphadenectomy. However, after
18 months, a biochemical recurrence occurred (PSA
1.26 μg/l), and FCH PET/CT showed several FCH-positive,
pathological enlarged lymph nodes, compatible with meta-
static disease. Overall, following lymphadenectomy, all of
the patients showed PSA progression at some point in time.
In three patients, lymph node metastases were confirmed
by progressive FCH accumulation at the follow-up FCH
PET/CT taken under conditions of a rising PSA level
(Fig. 2). In seven cases, the FCH-positive lymph nodes
were clearly enlarged and met malignancy criteria on CT
and/or MRI imaging. In one patient with a FCH-positive
lymph node, a decreasing PSA level during radiotherapy
(RT) of the positive lymph node confirmed metastatic
disease. Lymph node metastases could not be confirmed in
five patients.
Bone metastases
Pathological FCH accumulation in osseous structures was
seen in 17 patients (mean SUVmax 6.7; range 1.7–12; SD
3.04).Metastases to the bonewas confirmed by bone scan (n=
11) (Fig. 3), MRI (n=3) (Fig. 4) and CT morphology (n=3).
FCH PET/CT in patients with PSA <2 μg/l
Fourteen patients with PSA levels ≤2 μg/l were examined.
Of these 14 patients, four were receiving antihormonal
therapy at the time of the FCH PET/CT scan. Of the 14 FCH
PET/CT scans, ten demonstrated pathological accumulation,
whereas PET/CT could not demonstrate recurrent disease in
the remaining four cases. Only one of the four patients with a
negative PET/CT scan at PSA <2 μg/l was receiving
antihormonal therapy. The overall sensitivity of FCH PET/
CT imaging in patients with PSA levels <2 μg/l in our
limited number of cases was 71%, in patients not receiving
antihormonal therapy, 70% and in patients receiving anti-
hormonal therapy with a measurable PSA <2 μg/l, 75%.
Patient details are presented in Table 6. The overall
sensitivity of FCH PET/CT at any PSA level was 86%,
and at PSA levels of >2 μg/l, 87%. (Sensitivity without
antihormonal therapy at any PSA level was 83%, and at
PSA >2 μg/l without antihormonal therapy, 86%. Sensitiv-
ity at any PSA level in patients with HT was 84% and at
>2 μg/l, 88%).
FCH PET/CT in patients receiving antihormonal therapy
Of the 13 patients examined with FCH PET/CT who were
receiving antihormonal therapy, only two examinations did
not show any pathological FCH accumulation even though
PSA levels were pathological. In the other 11 patients, at
least one site of pathological FCH uptake was confirmed to
be metastatic disease or local recurrence (Fig. 5). Patient
Table 5 Patients without FCH accumulation (n.a. not available)
Age (years) PSA Previous therapy Time after initial treatment TNM GS HT Verification
46 0.36 RP 9 months pT2c 7 N PSA drop after RT (FN LR)
63 0.5 RP 3 years, 2 months pT2a 6 N MRI (FN LR)
69 0.52 RP, RT 2 years, 3 months pT2b cN0 6 N PSA drop after RT (FN LR)
69 1.9 RP, RT 6 years, 4 months n.a. n.a. Y Under HT
67 2.1 RP 8 years, 5 months pT3a R1 n.a N Local biopsy positive
74 2.12 RT, HT,
Ablatherm
5 years, 3 months pT2b 5 N Local biopsy positive
68 3.41 RP, RT 7 years, 10 months pT2a n.a. N no PSA drop after RT
(FN distant disease)
65 3.5 RP, HT 7 years, 1 months pT3a pN0 8 Y PSA before HT 13
72 4.4 RP 5 years, 10 months pT4 7 N PSA drop after RT (FN LR)
76 4.77 RP 8 years, 10 months pT3a 5 N PSA drop after RT (FN LR)
74 10.69 RP 7 years, 3 months pT2b 6 N Very high PSA
PSA, Prostrate specific antigen; GS, Gleason score; RP, radical prostatectomy; HT, antihormonal therapy; RT, radiotherapy external beam or
brachytherapy, LAD, lymphadenectomy; FN, false negative; MRI, magnetic resonance imaging; TNM, cancer staging system; LR, local recurrence
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details are presented in Table 7. In general, pathological
FCH uptake was seen when the tumour became hormone
resistant, i.e., when the PSA started rising again. In the two
cases with no pathological FCH accumulation, the patients
had just started receiving antihormonal treatment and their
PSA levels were dropping.
Discussion
When assessing the accuracy of FCH PET/CT imaging in
prostate cancer, the patient population has to be split into
two major subgroups: (1) patients with newly diagnosed
prostate cancer and (2) patients with biochemical recurrence
of prostate cancer after initial treatment.
On the basis of our data, FCH PET/CT imaging seems to
have a limited value for initial staging of prostate cancer.
The patients we examined with FCH PET/CT for initial
staging all had proven prostate cancer and localizing the
tumour within the prostate was not the main goal in our
study. In a previous study we showed that FCH PET/CT is
not appropriate for initial T staging due to the limited
spatial resolution of PET that does not enable the
assessment of capsular infiltration, which in turn defines
T3 tumours [11]. Additionally, pathological FCH accumu-
lation occurs not only in prostate cancer, but also in benign
prostatic hyperplasia and prostatitis. In some studies the
authors showed that it was possible to localize cancer
within the prostate [12, 13].
When the SUVmax values obtained in our population
are compared to previously published data on physiological
uptake in various body regions, malignant and benign
lesions clearly demonstrate higher uptake values [11].
SUVmax values measured in lymph node metastases at
initial staging (mean 5.04; range 4.9–5.2; SD 0.21) and at
restaging (mean 4.3; range 1–14; SD 2.3) were higher than
those in subcutaneous fat (mean 0.2 ± 0.1; range 0.1–0.3).
Interestingly, SUVmax values of bone metastases at initial
Fig. 1 a MIP imaging, b top to
bottom computed tomography
(CT), positron emission tomog-
raphy (PET), fusion, all axial.
Images are of a 70-year-old
patient with a history of surgery
8 years prior and radiotherapy
5 years prior. [18F]-Fluorocho-
linefluoromethyldimethyl-2-
hydroxyethyl-ammonium (FCH)
PET/CT shows local recurrence
(bold arrow) proven by biopsy
(Gleason 7). Note the FCH in
the veins of the right arm after
insufficient flushing after FCH
injection (thin arrow)
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staging (mean SUVmax 6.3; range 1.8–13.9; SD 4.21) and at
restaging (mean SUVmax 6.7; range 1.7–12; SD 3.04) were
higher than those of lymph node metastases and physiological
uptake in bone of the lumbar spine (mean 1.3 ± 0.5; range 0.2–
1.9). In proven local recurrence, SUVmax values (mean 2.9;
range 1.2–9.7; SD 1.7) were lower than those in lymph node
metastases and higher than those in subcutaneous fat (mean
0.2 ± 0.1; range 0.1–0.3) or in the bladder (mean 0.4 ± 0.1;
range 0.2–0.7). However, no cutoff can be given since almost
all detected lesions were due to malignancy, and only one
single lesion was due to inflammation (false positive FCH
uptake in one lymph node, SUVmax 1.9).
FCH PET/CTcan be helpful to guide biopsy if a patient has
persistent elevated PSA levels but the biopsies remain
negative for tumour. One major limitation of FCH PET/CT
for initial staging is the general inability of PET imaging to
detect micrometastases. The identification of occult lymph
node metastases appears to have an impact on the outcome of
patients with prostate cancer [14]. Patients with occult lymph
node metastases show significantly increased risk of prostate
cancer recurrence and death. Another study suggests that
more extensive pelvic lymphadenectomy in patients under-
going radical prostatectomy could improve the accuracy of
staging and have a positive impact on disease-free survival
and, perhaps, on overall-survival [15]. Often, only the
obturator lymph nodes are resected. Schumacher et al.
showed in their study that by resecting lymph nodes along
the internal iliac artery, a larger amount of metastases was
found. The proportion of patients with nodes either
exclusively in this area or in combination with another
location was 59% [16]. The sentinel lymph node concept
might be the solution for accurate initial nodal staging in
prostate cancer patients [17]. The method is widely accepted
in melanoma, breast cancer and ENT tumours.
FCH PET/CT is well able to depict bone metastases of
prostate cancer; nevertheless, [18F]fluoride PET has a
greater sensitivity [18]. A possibility to enhance the
detection rate of bone metastases on FCH PET/CT scans
is late imaging at 65–200 min p.i. [10]. Whereas FCH
accumulation in bone metastases on late imaging rises
compared to early imaging (5–15 min p.i.), the time point
of imaging has no influence on FCH accumulation in local
recurrence or lymph node metastases. One could consider
imaging the region of the prostate soon after the injection of
Fig. 2 a MIP imaging, b top to bottom CT, PET, fusion, all axial, c
MIP, d top to bottom CT, PET, fusion, all axial (c, d 11 months later).
Images of a 58-year-old patient, with a history of surgery 2 years,
4 months previously; PSA 1.07 μg/l. Scan was initially evaluated as
normal. In retrospect, a normal-sized lymph node (bold arrow) shows
increased FCH activity. FCH in the ureter on the left side (thin arrow).
c, d 11 months later, PSA is now 5.25 μg/l. FCH PET/CT shows one
clearly enlarged and FCH-active lymph node in the iliac extern region
on the right side (bold arrow)
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FCH in order to evaluate this region without a radiotracer in
the bladder and performing whole body images approxi-
mately 1 h later. The disadvantage of this method would be
that the patient has to be positioned on the scanner twice.
FCH PET/CT shows promising results in localizing
recurrent PC. PSA doubling time is currently the best
predictor of tumour progression. Nonetheless, there is no
consensus on diagnostic work-up that should be performed.
A PSA level of >0.2 μg/l has been described as a definition
for recurrent PC after prostatectomy [19]. Curative salvage
therapy is most likely to succeed when realized in patients
with PSA levels of <2 μg/l [2]. In the limited number of
patients in our study that were examined at PSA levels of
<2 μg/l, the overall sensitivity for detecting recurrent
disease was 71%. The overall sensitivity in detecting
recurrent disease at any PSA level in our study was 86%.
No definite PSA cut-off level can be given – i.e. from when
on FCH PET/CT can reliably detect recurrent disease. The
PSA level is not the only factor determining whether
pathological FCH accumulation will be found or not.
Factors such as PSA doubling time, time to recurrence
after initial therapy and PSA and the Gleason score at initial
therapy seem to have an influence on the accumulation of
FCH as well. In our study in patients with recurrent PC, we
found several normal-sized lymph nodes with minimally
increased FCH accumulation above the background that
turned out to be metastases, proven by histopathology or
increasing FCH-uptake on follow-up PET/CT (Fig. 2).
As bowel, ureter and lymph nodes can be very close
together in the pelvis and abdomen, coregistration with CT is
of great importance. The detection of small lymph node
metastases with only minimal radiotracer accumulation on
FCH PET alone is impossible. Pelvic MRI with surface coils
and the use of superparamagnetic particles provide the
sensitivity and the specificity which have never been
obtained by the sole measurement of node size of the
lymphatic chains draining the prostate gland and might be
the future of lymph node imaging in prostate cancer [20, 21].
According to Sella et al.,MRI with endorectal coil depicts a
high proportion of local recurrence after prostatectomy [22].
The advantage of PET/CT is, on one hand, the combination
of functional and anatomical imaging of a large FOVand, on
the other hand, an all-in-one examination.
In terms of FCH PET/CT imaging of patients receiving
antihormonal therapy, Heinisch et al. showed that FCH
PET/CT can be positive in these patients, even at very low
PSA levels [23]. Pathological accumulation will occur in
patients with hormone-resistant tumour tissue, as indicated
Fig. 3 a Bone scan, b MIP, c
top to bottom CT, PET, fusion,
all axial. Images of a 76-year-
old patient with a history of
surgery 17 years prior (staging
pT3b), radiotherapy of recur-
rence 16 years prior and orchi-
ectomy 1 year, 1 month prior.
FCH PET/CT confirms multiple
osseous metastases also seen on
the bone scan
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by a rising PSA under therapy. On the other hand, patients
with hormone-dependent tumours receiving antihormonal
therapy will not show pathological FCH accumulation [24].
In the case of distant metastases, current treatment
options include only therapies with palliative intent, such
as radiotherapy to palliate bone pain and/or prevent
impending fracture, palliative radionuclide therapy, ortho-
pedic surgery to prevent or repair fractures, analgesics and
bisphosphonates, all of which can significantly reduce the
risk of skeletal complications and delay their onset. If only
systemic therapy is intended, the value of imaging is
questionable. In such a case, measurement of PSA and
patient questioning might be sufficient to evaluate therapy
response. On the other hand, if focused therapy, such as
radiotherapy of lymph node metastases or bone metastases,
is intended, FCH PET/CT can nicely demonstrate therapy
response (Fig. 4). Another indication for FCH PET/CT in
recurrent disease can be the exclusion of distant metastases
Fig. 4 a MIP imaging, b top to bottom CT, PET, fusion, all axial, c
MIP, d top to bottom CT, PET, fusion, all axial, e top to bottom CT,
PET, fusion, all axial (c–e 1 year later). Images of a 59-year-old
patient with a history of radiotherapy 3 years prior. Initial stage T2c,
PSA 41 μg/l, Gleason 8. PSA is now 2.00 μg/l. FCH PET/CT reveals
bone metastasis (bold arrow) verified by MRI in addition to a known
local recurrence. One year later (c–e) the PSA had dropped to 0.7 μg/l but
started rising again. PSA is now 1.5 μg/l. FCH PET/CT shows no active
tumour in the radiated bone metastasis (bold arrow). New metastasis in
L 4 (thin arrow) in addition to the still existing local recurrence
Table 6 Patients with PSA <2 μg/l
Age (years) PSA PET/CT Verification HT Therapy
79 0.35 LR, BM Bone scan Yes HT
46 0.36 No PSA drop No RP
66 0.4 LR, LN PSA drop Yes RP
63 0.5 No MRI LR No RP
69 0.52 No PSA drop No RP, RT
62 0.7 LR PSA drop No RP
68 0.81 BM CT morphology No RP, HT
81 1.2 LR MRI Yes (Orchiectomy) RP, RT, HT
61 1.26 LN CT morphology No RP, LAD
75 1.29 LR PSA drop RP
60 1.5 LR, BM Biopsy, MRI No RT HT RT bone met
69 1.9 No PSA Yes RP, RT
63 1.96 LR, BM Bone scan No RP
60 2.0 LR, BM Biopsy, MRI No
LR, Local recurrence; BM, bone metastasis; LN, lymph node metastasis; No, no FCH accumulation; HT, antihormonal therapy
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in patients with bioptically proven local recurrence of PC
and planned local salvage therapy, such as radiotherapy or
high-intensity focused ultrasound therapy [25].
In our opinion, the optimal diagnostic work-up after the
initial diagnosis of PC consists of a bone scan or [18F]-
fluoride PET/CT to rule out bone metastases combined with
sentinel lymph node dissection to attain accurate lymph
node staging [26]. FCH PET/CT does not seem to be the
ideal imaging modality for initial staging of PC. In the case
of biochemical recurrence, however, we believe that FCH
PET/CT imaging is of great help. The sensitivity of 71% in
localizing recurrent disease at PSA levels <2 μg/ is not very
high, but at the moment there is no other imaging modality
that performs better.
The considerable limitations of the study include
surgical strategies at initial staging as well as the inclusion
of a heterogeneous group of patients with possible recurrent
disease. At staging surgery, a more extensive lymph node
dissection procedure would have been preferred; however,
dissection limited to the obturator fossa is the procedure of
choice for many urological surgeons. Therefore, possible
involved lymph nodes outside the obturator fossa region
could have been missed. Further, an added contrast-
enhanced CT part could possibly have improved the
diagnostic accuracy. However, all missed lymph nodes
were smaller than 1 cm and as such do not meet CT criteria
for malignancy. The heterogeneity in treatment and time to
biochemical recurrence of patients with recurrent prostate
cancer reflects the typical referral pattern.
Conclusion
[18F]-Choline PET/CT does not seem to be suitable for the
initial staging of prostate cancer due to its low sensitivity in
detecting lymph node metastases. At the present time,
[18F]-choline PET/CT as a single-step exam seems to be the
most accurate imaging modality to identify the location of
Fig. 5 Top to bottom CT, PET, fusion, all axial. Images of a 66-year-
old male with a history of surgery 3 years, 5 months prior. The patient
was receiving antihormonal treatment. Staging PT2b pN1, Gleason 7,
PSA 4.02 μg/l. The PSA is now 0.4 μg/l. FCH PET/CT revealed
lymph node metastasis (bold arrow) (verified by PSA drop during
radiotherapy of the lymph node)
Table 7 Patients receiving antihormonal treatment
Age (years) PSA PET/CT Verification
79 0.35 LR, BM Bone scan
66 0.4 LR, LN RT of LN → PSA drop
81 1.2 LR MRI
69 1.9 No
70 2.5 LR Histopathology
58 2.6 BM Bone scan
65 3.5 No
66 5.8 LN CT morphology
69 18 LN, BM CT morphology, bone scan
65 42 LR, LN, BM LN histopathology, bone scan
76 46.3 BM Bone scan
60 54.6 BM CT morphology
69 73 LR, LN, BM CT morphology, bone scan+
LR, local recurrence; BM, bone metastasis; LN, lymph node
metastasis; No, no FCH accumulation.
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recurrent disease, even though the sensitivity rate is rather
moderate. A possible future indication for FCH PET/CT
might be therapy assessment of novel therapeutic strategies.
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